Entasis Therapeutics, a Waltham, Mass.-based company focused on the discovery and development of anti-infective products, completed a $50m Series B financing.
The round was led by Clarus with participation from Frazier Healthcare Partners, Novo A/S, and Eventide Funds, which joined founding investor AstraZeneca.
In conjunction with the funding, Chairman Nicholas Galakatos, Ph.D., Co-founder and Managing Director of Clarus; James Topper, M.D., Ph.D., Managing General Partner of Frazier Healthcare Partners; and Peter Tuxen Bisgaard, Senior Partner of Novo Ventures (US) Inc., joined Entasis’ Board of Directors.
The company intends to use the funds to advance its pipeline of clinical and preclinical products.
Led by Manos Perros, Ph.D., President and Chief Executive Officer, Entasis is developing a portfolio of innovative cures for serious drug-resistant bacterial infections. its pipeline consists of clinical and preclinical-stage antibiotics for major Gram-negative infections, which target essential bacterial processes using a discovery platform integrated with clinical capabilities.